People who took Pfizer's antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn't, the study said. Read this story at CNBC , NBC 5 Dallas-Fort Worth
People who took Pfizer's antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn't, the study said. Read this story at CNBC , NBC 5 Dallas-Fort Worth
More from CNBC | Coronavirus Breaking News: Business Breaking news Biotechnology Biotech and Pharmaceuticals Pharmaceuticals Health care industry Pfizer Inc business news cnbc Articles US: News Business News Health & Science source:tagname:CNBC US Source